Galvus Tablets 50Mg (1 Box = 2 Strips) (1 Strip = 14 Tablets)

Name: Galvus Tablets 50Mg (1 Box = 2 Strips) (1 Strip = 14 Tablets)
Brand: NOVARTIS PHARMACEUTICALS
Price: 1790.32

Brand : novartis pharmaceuticals

Rs. 1,790.32

Rs. 1,884.65

|

QUICK DELIVERY

Galvus Tablets Specification

Requires Prescription (YES/NO)

Yes

Generics

Vildagliptin

Used For

Diabetes

How it works

The administration of vildagliptin results in a rapid and complete inhibition of DPP-4 activity, resulting in increased fasting and postprandial endogenous levels of the incretin hormones GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide).

Galvus Tablets Usage And Safety

Dosage

Vildagliptin

Side Effects

Monotherapy Common: Dizziness. Uncommon: Hypoglycemia, headache, edema peripheral, constipation & arthralgia. Very Rare: Upper respiratory tract infection & nasopharyngitis. Combination with Metformin Common: Hypoglycemia, tremor, headache, dizziness & nausea. Uncommon: Fatigue. Combination with Sulfonylurea Common: Hypoglycemia, tremor, headache, dizziness & asthenia. Uncommon: Constipation. Very Rare: Nasopharyngitis. Combination with Thiazolidinedione Common: Weight increase & edema peripheral. Uncommon: Hypoglycemia, headache & asthenia. Combination with Metformin and Sulfonylurea Common: Hypoglycemia, dizziness, tremor, hyperhidrosis & asthenia. Combination with Insulin Common: Decreased blood glucose, headache, chills, nausea, gastroesophageal reflux disease. Uncommon: Diarrhea & flatulence.

Drug Interactions

Vildagliptin has a low potential for interactions with co-administered medicinal products. Since vildagliptin is not a cytochrome P (CYP) 450 enzyme substrate and does not inhibit or induce CYP450 enzymes, it isnot likely to interact with active substances that are substrates, inhibitors or inducers of these enzymes. As with other oral antidiabetic medicinal products the hypoglycemic effect of vildagliptin may be reduced by certain active substances, including thiazides, corticosteroids, thyroid products and sympathomimetics.

Indication

Vildagliptin is indicated for the treatment of type 2 diabetes mellitus in adults:As monotherapy - In patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.As dual oral therapy in combination with - Metformin, in patients with insufficient glycemic control despite maximal tolerated dose of monotherapy with metformin.- Sulfonylurea, in patients with insufficient glycemic control despite maximal tolerated dose of a sulfonylurea and for whom metformin is inappropriate due to contraindications or intolerance.- Thiazolidinedione, in patients with insufficient glycemic control and for whom the use of a thiazolidinedione is appropriate. As triple oral therapy in combination with- Sulfonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycemic control.Vildagliptin is also indicated for use in combination with insulin (with or without metformin) when diet and exercise plus a stable dose of insulin do not provide adequate glycemic control.

When not to Use

Vildagliptin is contraindicated in patients with known hypersensitivity to vildagliptin or to any excipient of the product.

Galvus Tablets Precautions

Precaution

Rare cases of hepatic dysfunction (including hepatitis) have been reported. Liver function tests should be performed prior to the initiation of treatment. Liver function should be monitored during treatment with vildagliptin at three-month intervals during the first year and periodically thereafter. Patients who develop jaundice or other signs suggestive of liver dysfunction should discontinue vildagliptin.

Galvus Tablets Warnings

Warning 1

Vildagliptin should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.

Warning 2

In diabetic patient, monitoring for skin disorders, such as blistering or ulceration, is recommended.

Warning 3

Use of vildagliptin has been associated with a risk of developing acute pancreatitis. If pancreatitis is suspected, vildagliptin should be discontinued and if acute pancreatitis is confirmed, vildagliptin should not be restarted. Caution should be exercised in patients with a history of acute pancreatitis.

Download the Dvago App